ArticleTrials2025
Sedation-related adverse events in gastrointestinal endoscopy (CH-ESC study): study protocol for a prospective, observational cohort study in a Chinese tertiary hospital.
Article in Trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSedation is commonly employed during gastrointestinal endoscopy (GIE), yet sedation-related adverse events (SRAEs)-particularly cardiopulmonary complications-remain a critical safety concern. While large cohort studies from Western countries have identified key risk factors such as advanced age, obesity, and high ASA classification, data on SRAEs within the Chinese population are scarce. This study aims to assess the prevalence, characteristics, and risk factors associated with SRAEs in a Chinese tertiary hospital setting. METHODS/
designThis prospective, observational cohort study is being conducted at the Changhai Digestive Endoscopy Center, one of the largest GIE facilities in China. Between November 2023 and November 2026, we aim to recruit 100,100 patients undergoing sedated GIE. The primary outcome is the incidence of SRAEs during the endoscopy procedure. Comprehensive data on patient demographics (e.g., age, BMI), sedation parameters (e.g., medications used, sedation depth), and endoscopic procedure specifics (e.g., type and duration) will be collected, and these candidate factors will be entered into multivariate logistic regression analysis to identify independent predictors of SRAEs. DISCUSSION: With the increasing application of sedation during GIE, preventing and managing SRAEs is of paramount importance. The outpatient nature and short duration of these procedures complicate accurate reporting, potentially leading to an underestimation of SRAEs. Beyond established risk factors, this study seeks to explore emerging predictors, including waist-to-hip ratio and frailty assessments. Although this is a single-center study, it represents the first large-scale investigation of SRAEs in China and may contribute to improved risk stratification models and enhanced patient safety protocols.
trial registrationChinese Clinical Trial Register, ChiCTR2300078784. Registered on December 18, 2023. STUDY STATUS: Recruitment began on December 1, 2023. As of July 31, 2024, 6023 participants have been enrolled. The study team plans to request an extension from the Ethics Committee to continue enrolment until December 31, 2028.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.